• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Evotec SE

    4/30/24 6:00:33 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email
    NT 20-F 1 tm2410079d2_nt20f.htm NT 20-F

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 12b-25

     

    SEC FILE NUMBER

    001-34041

    CUSIP NUMBER

    30050E105

     

    NOTIFICATION OF LATE FILING

     

    (Check One) ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

     

    For Period Ended: December 31, 2023

     

    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q

     

    For the Transitional Period Ended: N/A

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

     

    PART I - REGISTRANT INFORMATION
     
    Evotec SE
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    Essener Bogen 7
    Address of Principal Executive Office (Street and Number)
     
    22419 Hamburg, Germany
    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ¨ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Evotec SE (the “Company”) is unable to file its Annual Report on Form 20-F for the period ended December 31, 2023 (the “2023 Form 20-F”) by the prescribed due date.

     

    BDO is the Company’s independent public accountant and annually audits the Company’s consolidated financial statements. In the ordinary course, the Company engages firms other than BDO to perform audits of certain subsidiaries whose financial results are consolidated into the Company’s consolidated financial statements due to statutory regulations regarding local rotation of audit firms. In the course of the Company and BDO finalizing the Company’s financial statements and audit for the fiscal year ended December 31, 2023, affiliates of Ernst & Young (“EY”) that had audited the financial statements of the Company’s French and Italian subsidiaries (Evotec (France) SAS and Aptuit (Verona) S.r.l.) informed the Company and BDO that EY is not independent under the rules of the Securities and Exchange Commission and the Public Company Accounting Oversight Board as a result of certain services provided by a different EY affiliate to another of the Company’s subsidiaries for which the EY affiliate was paid approximately 50,000 Euros. As a result, we have engaged BDO to re-audit the 2023 financial statements of Evotec (France) SAS and Aptuit (Verona) S.r.l.

     

    Due to the time and effort required to audit the 2023 financial statements of Evotec (France) SAS and Aptuit (Verona) S.r.l., the Company will be unable, without unreasonable effort or expense, to complete and file the 2023 Form 20-F within the prescribed time period. The Company is working with BDO to file its 2023 Form 20-F as promptly as possible, however there can be no assurance with respect to the timing of completion of the filing.

     

     

     

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification  

     

      Laetitia Rouxel   +49 40   560810  
      (Name)   (Area Code)   (Telephone Number)  

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?

     

      If answer is no, identify report(s). x Yes ¨ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

        x Yes ¨ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company expects its full-year 2023 results of operations will show a 4% increase in revenues, a net loss of approximately €71.2 million driven principally by the costs to respond to the cyber incident and losses from investments and a 34% decrease in Adjusted EBITDA (which excludes changes in contingent consideration, income from bargain purchase and impairments in goodwill, other intangible and tangible assets, total non-operating results, as well as other items that in magnitude, nature or occurrence would distort the presentation of the financial statements) compared to the corresponding period for the prior fiscal year.

     

    Cautionary Note Regarding Forward-Looking Statements  

     

    This Form 12b-25 includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the Company’s ability to file the 2023 Form 20-F and preliminary estimated revenues for the year ended December 31, 2023. Such forward-looking statements are based on assumptions about many important factors, which could cause actual results to differ materially from those in the forward-looking statements, including the accuracy of the Company’s assumptions underlying its revenue estimation for the period ended December 31, 2023 and other risks identified in the Company’s most recent Annual Report on Form 20-F and other SEC filings, all of which are available on the Company’s website. The Company does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.  

     

     

     

     

    EVOTEC SE

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 30, 2024 By: /s/ Laetitia Rouxel
          Laetitia Rouxel
          Chief Financial Officer  
          (Principal Financial Officer)

     

     

     

    Get the next $EVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    2/3/2026Buy
    Berenberg
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Evotec SE

    Berenberg initiated coverage of Evotec SE with a rating of Buy

    2/3/26 6:55:14 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE upgraded by Deutsche Bank

    Deutsche Bank upgraded Evotec SE from Sell to Hold

    4/24/25 7:18:16 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE downgraded by Jefferies

    Jefferies downgraded Evotec SE from Buy to Hold

    10/7/24 7:52:16 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    SEC Filings

    View All

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    1/16/26 7:00:26 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    1/13/26 7:32:25 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    1/8/26 10:09:27 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

    Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l

    1/22/25 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

    Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade

    12/11/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec Announces Change in Management Board

    Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen

    11/29/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Leadership Updates

    Live Leadership Updates

    View All

    Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

    Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm

    9/26/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE: Results of the Annual General Meeting 2024

    Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina

    6/10/24 12:15:00 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

    HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of

    4/23/24 3:00:00 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Financials

    Live finance-specific insights

    View All

    Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

    Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda

    11/6/24 1:20:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

    HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we

    10/30/24 3:30:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

    Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G

    8/14/24 1:30:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Evotec SE

    SC 13D - Evotec SE (0001412558) (Subject)

    11/8/24 9:43:55 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evotec SE (Amendment)

    SC 13G/A - Evotec SE (0001412558) (Subject)

    2/14/24 4:55:09 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evotec SE (Amendment)

    SC 13G/A - Evotec SE (0001412558) (Subject)

    2/2/23 1:24:31 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care